Grupo Espanol de Tumores Neuroendocrinos (GETNE)   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Barcelona Spain (2004)

Organization Overview

First Clinical Trial
2010
NCT01280201
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Grupo Espanol de Tumores Neuroendocrinos

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma, Follicular (Phase 2)

Adenoma, Islet Cell (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Papillary (Phase 2)

Digestive System Neoplasms (Phase 2)

Endocrine Gland Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 3)

Pancreatic Neoplasms (Phase 2)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Thyroid Cancer, Papillary (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 17